Clinical Association Between Celiac Disease and Intussusception in Children
Launched by MERNA HAMDY KAMAL MOHAMMED · Mar 31, 2025
Trial Information
Current as of July 28, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the relationship between celiac disease and a condition called intussusception in children. Celiac disease is an autoimmune disorder where eating gluten (a protein found in wheat, barley, and rye) damages the small intestine. Intussusception occurs when part of the intestine folds into another part, which can cause blockages. The researchers want to see if children with celiac disease are more likely to develop intussusception compared to those without the disease.
To participate in the trial, children must be between 6 months and 18 years old, have a confirmed diagnosis of celiac disease, and have been diagnosed with intussusception through imaging tests. Parents or guardians will need to give their consent for their child to join. However, children with certain gastrointestinal problems, those who have had abdominal surgery, or those on specific medications that weaken the immune system cannot participate. The trial is not yet recruiting participants, but it aims to gather important information about how these two conditions may be connected in young patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children aged 6 months to 18 years Diagnosed with celiac disease based on serology and biopsy Diagnosed with intussusception confirmed by imaging Parent or legal guardian provides informed consent
- Exclusion Criteria:
- • Children with known gastrointestinal abnormalities other than celiac disease History of abdominal surgery Incomplete or unavailable medical records Patients on immunosuppressive therapy
About Merna Hamdy Kamal Mohammed
Merna Hamdy Kamal Mohammed is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a robust background in clinical operations and regulatory compliance, she leads initiatives that focus on innovative therapeutic interventions across various therapeutic areas. Her expertise in trial design and execution ensures that studies are conducted with the highest ethical standards and scientific rigor. Merna is passionate about fostering collaboration among multidisciplinary teams to drive the successful development of new treatments, ultimately enhancing the quality of care available to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported